Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
MedImmune LLC |
---|---|
Information provided by: | MedImmune LLC |
ClinicalTrials.gov Identifier: | NCT00435227 |
Condition | Intervention | Phase |
---|---|---|
Healthy |
Biological: MEDI-524 Other: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intramuscular Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Outpatient Treatment of Children With RSV Illness |
Enrollment: | 12 |
Study Start Date: | March 2007 |
Study Completion Date: | July 2008 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
MEDI-524
|
Biological: MEDI-524
30 mg/kg of MEDI-524
|
2: Placebo Comparator
Placebo
|
Other: Placebo
30 mg/kg of Placebo
|
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to determine the effect of a single 30 mg/kg IM dose of motavizumab on viral load and motavizumab levels in the upper respiratory tract of children who present with RSV illness but who do not require hospitalization. Using 1:1 randomization, 30 mg/kg motavizumab or placebo will be administered as soon as possible after a child's diagnosis of RSV and his/her eligibility for the study has been confirmed.
Ages Eligible for Study: | up to 12 Months |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | M. Pamela Griffin, M.D. | MedImmune LLC |
Responsible Party: | MedImmune Inc. ( M. Pamela Griffin, M.D ) |
Study ID Numbers: | MI-CP146 |
Study First Received: | February 13, 2007 |
Last Updated: | September 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00435227 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Respiratory Syncytial Viruses |
Antibodies, Monoclonal Virus Diseases Antibodies Healthy Immunoglobulins |